Item 5. Other Information
ITEM
5. OTHER
INFORMATION
None.
43
ITEM
6. EXHIBITS
INDEX
TO EXHIBITS
Exhibit
Incorporation
By Reference
Number
Exhibit
Description
Form
SEC
File No.
Exhibit
Filing
Date
3.1
Amended and Restated Certificate of Incorporation
8-K
333-178230
3.2
7/25/2013
3.2
Certificate of Designation of Series A Junior Participating Preferred Stock.
8-K
001-36357
3.1
12/1/2015
3.3
Certificate of Increase of Series A Junior Participating Preferred Stock.
8-K
001-36357
3.1
11/1/2021
4.1
Second Amended and Restated Stockholder Rights Plan
8-K
001-36357
4.1
11/1/2021
10.1*+
License Agreement, dated October 14, 2021, by and between Lipocine Inc. and Antares Pharma, Inc.
10.2*+
Amendment No. 1 to Commercial Manufacturing Services and Supply Agreement between Lipocine Inc. and MW Encap Ltd. dated October 13, 2021
31.1*
Certification
of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*
Certification
of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*
Certification
of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. 1350 (1)
32.2*
Certification
of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. 1350 (1)
101.INS *
XBRL
Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within
the Inline XBRL document.
101.SCH *
Inline
XBRL Taxonomy Extension Schema Document
101.CAL *
Inline
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF *
Inline
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB *
Inline
XBRL Taxonomy Extension Labels Linkbase Document
101.PRE *
Inline
XBRL Taxonomy Extension Presentation Linkbase Document
104
Cover
Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because
its XBRL tags are embedded within the Inline XBRL document.
*
Filed
herewith
+
Certain
portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K. The Registrant hereby undertakes to furnish
to the SEC, upon request, copies of any such instruments.
(1)
This
certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and
is not to be incorporated by reference into any filing of the Registrant under the Securities Act, or the Exchange Act (whether made
before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.
44
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
Lipocine
Inc.
(Registrant)
Dated:
November 10, 2021
/s/
Mahesh V. Patel
Mahesh
V. Patel, President and Chief
Executive
Officer
(Principal
Executive Officer)
Dated:
November 10, 2021
/s/
Morgan R. Brown
Morgan
R. Brown, Executive Vice President
and
Chief Financial Officer
(Principal
Financial and Accounting Officer)
45
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.